Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SRZN Stock Forecast 2026-2027
$20.00
Current Price
$171.43M
Market Cap
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to SRZN Price Targets
+110.0%
To High Target of $42.00
+80.0%
To Median Target of $36.00
+60.0%
To Low Target of $32.00
SRZN Price Momentum
+4.9%
1 Week Change
-7.5%
1 Month Change
+68.8%
1 Year Change
-11.5%
Year-to-Date Change
-19.8%
From 52W High of $24.94
+239.0%
From 52W Low of $5.90
📊 TOP ANALYST CALLS
Did SRZN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Surrozen is one of their latest high-conviction picks.
Latest SRZN Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, SRZN has a bullish consensus with a median price target of $36.00 (ranging from $32.00 to $42.00). The overall analyst rating is N/A (N/A/10). Currently trading at $20.00, the median forecast implies a 80.0% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Matthew Caufield at HC Wainwright & Co., suggesting a 60.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SRZN Analyst Ratings
3
Buy
0
Hold
0
Sell
SRZN Price Target Range
Low
$32.00
Average
$36.00
High
$42.00
Current: $20.00
Latest SRZN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SRZN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 12, 2025 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $32.00 |
| Apr 2, 2025 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $32.00 |
| Jan 30, 2025 | HC Wainwright & Co. | Matthew Caufield | Buy | Initiates | $32.00 |
| Jan 3, 2025 | Guggenheim | Yatin Suneja | Buy | Upgrade | $45.00 |
| Nov 29, 2022 | JP Morgan | Eric Joseph | Underweight | Downgrade | $N/A |
| Nov 18, 2022 | Guggenheim | Yatin Suneja | Neutral | Downgrade | $N/A |
| Nov 17, 2022 | B of A Securities | Tazeen Ahmad | Underperform | Downgrade | $1.00 |
| Oct 17, 2022 | JP Morgan | Eric Joseph | Neutral | Initiates | $N/A |
| May 27, 2022 | B of A Securities | Tazeen Ahmad | Neutral | Downgrade | $5.00 |
| Oct 11, 2021 | B of A Securities | Buy | Initiates | $N/A | |
| Sep 15, 2021 | Guggenheim | Buy | Initiates | $N/A | |
| Sep 7, 2021 | Stifel | Buy | Initiates | $N/A |
Surrozen, Inc. (SRZN) Competitors
The following stocks are similar to Surrozen based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Surrozen, Inc. (SRZN) Financial Data
Surrozen, Inc. has a market capitalization of $171.43M with a P/E ratio of -0.9x. The company generates $3.60M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -90.2% quarter-over-quarter, while maintaining an operating margin of -1,107.3% and return on equity of +297.3%.
Valuation Metrics
Market Cap
$171.43M
Enterprise Value
$80.03M
P/E Ratio
-0.9x
PEG Ratio
0.0x
Price/Sales
49.1x
Growth & Margins
Revenue Growth (YoY)
-90.2%
Gross Margin
N/A
Operating Margin
-1,107.3%
Net Margin
0.0%
EPS Growth
-90.2%
Financial Health
Cash/Price Ratio
+47.4%
Current Ratio
13.2x
Debt/Equity
-0.3x
ROE
+297.3%
ROA
-33.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Surrozen, Inc. (SRZN) Business Model
About Surrozen, Inc.
What They Do
Develops therapeutics targeting the Wnt pathway.
Business Model
Surrozen, Inc. operates by researching and developing novel therapeutics that modulate the Wnt pathway, which is essential for cell communication and growth. The company generates revenue through the development of innovative therapies aimed at repairing damaged tissues and supporting maintenance in various diseases, particularly chronic conditions related to tissue degeneration.
Additional Information
The company's focus on the Wnt pathway positions it uniquely within the biotechnology sector, potentially leading to breakthroughs in regenerative medicine. Surrozen aims to address significant unmet medical needs, particularly in treating liver diseases and inflammatory bowel diseases, contributing to advancements in healthcare and pharmaceuticals.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
40
CEO
Mr. Craig C. Parker M.B.A.
Country
United States
IPO Year
2021
Website
www.surrozen.comSurrozen, Inc. (SRZN) Latest News & Analysis
Latest News
Quick Summary
Surrozen, Inc. (Nasdaq: SRZN) will present at two healthcare investor conferences, focusing on its targeted therapeutics for severe eye diseases.
Why It Matters
Surrozen's conference presentations may enhance visibility and attract investor interest, potentially impacting stock performance and funding opportunities in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Surrozen, Inc. granted 50,000 stock options to new CFO Andrew P. on November 6, 2025, as part of its strategy in developing therapeutics for severe eye diseases.
Why It Matters
Granting stock options to a new CFO indicates confidence in leadership and potential growth. It may signal future strategic initiatives, influencing stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Surrozen, Inc. reported its Q3 2025 financial results and business update, focusing on its targeted therapeutics for tissue repair and severe eye diseases.
Why It Matters
Surrozen's Q3 financial results and updates on Wnt pathway therapeutics could indicate growth potential and innovation in eye disease treatments, impacting investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Surrozen, Inc. (Nasdaq: SRZN) will present at a healthcare investor conference, focusing on its targeted therapeutics for severe eye diseases and modulation of the Wnt pathway.
Why It Matters
Surrozen's presentation at a healthcare investor conference may boost visibility and investor interest, potentially impacting stock performance and market perception of its Wnt pathway therapeutics.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Surrozen, Inc. (Nasdaq: SRZN) granted stock options for 45,710 shares to four new non-executive employees as an employment incentive on September 2, 2025.
Why It Matters
Surrozen's grant of stock options to new employees signals confidence in growth and innovation, potentially enhancing employee retention and aligning interests, impacting future stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Surrozen Reports Q2 Profit on Gains
5 months ago
Quick Summary
Surrozen reported a profit for Q2, attributed to gains during the quarter.
Why It Matters
Surrozen's Q2 profit signals strong financial performance and potential growth, which can enhance investor confidence and influence stock valuations positively.
Source: The Motley Fool
Market Sentiment:
Positive
Frequently Asked Questions About SRZN Stock
What is Surrozen, Inc.'s (SRZN) stock forecast for 2026?
Based on our analysis of 5 Wall Street analysts, Surrozen, Inc. (SRZN) has a median price target of $36.00. The highest price target is $42.00 and the lowest is $32.00.
Is SRZN stock a good investment in 2026?
According to current analyst ratings, SRZN has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $20.00. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SRZN stock?
Wall Street analysts predict SRZN stock could reach $36.00 in the next 12 months. This represents a 80.0% increase from the current price of $20.00. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Surrozen, Inc.'s business model?
Surrozen, Inc. operates by researching and developing novel therapeutics that modulate the Wnt pathway, which is essential for cell communication and growth. The company generates revenue through the development of innovative therapies aimed at repairing damaged tissues and supporting maintenance in various diseases, particularly chronic conditions related to tissue degeneration.
What is the highest forecasted price for SRZN Surrozen, Inc.?
The highest price target for SRZN is $42.00 from at , which represents a 110.0% increase from the current price of $20.00.
What is the lowest forecasted price for SRZN Surrozen, Inc.?
The lowest price target for SRZN is $32.00 from Matthew Caufield at HC Wainwright & Co., which represents a 60.0% increase from the current price of $20.00.
What is the overall SRZN consensus from analysts for Surrozen, Inc.?
The overall analyst consensus for SRZN is bullish. Out of 5 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $36.00.
How accurate are SRZN stock price projections?
Stock price projections, including those for Surrozen, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 15, 2026 4:25 AM UTC